Relationship between FAT10 expression and biological behaviors in infitrating ductal carcinoma of breast

Abstract

To study the relationship between FAT10 expression and biological behaviors in infitrating ductal carcinoma of breast. The expressions of diubiquitin (FAT10), estrogen receptor (ER), progesterone receptor (PR) and c-erbB2 in 50 cases of infitrating ductal carcinoma of breast were detected by immunohistochemistry. Western blot was used to detect FAT10 expression in MB-MDA-435, MB- MDA-435-transfected with FAT10 siRNA expression plasmid, MCF-7 and MCF-7-transfected with FAT10 expression plasmid, respectively. Transwell was used to detect invasion capability of MB- MDA-435, MB-MDA-435-transfected with FAT10 siRNA expression plasmid, MCF-7 and MCF-7-transfected with FAT10 expression plasmid. The expression intensity of FAT10 was significantly correlated to patho-grading, lymph nodes metastasis, distant metastasis and TNM staging (P<0.01), but not to age of patients and tumor sizes in infitrating ductal carcinoma of breast (P>0.05). The expression intensity of FAT10 in receptor- negative group was obviously stronger than that in receptor- positive group (P<0.01). The expression intensity of FAT10 in triple-negative breast cancer was significantly stronger than that in non- triple-negative breast cancer (P<0.01). The survival rate of patients with FAT10 positive expression was significantly lower than negative ones (P<0.05). Western blot results showed that FAT10 intensity in MB-MDA-435 significantly higher than that in MCF-7. Up-regulation expression of FAT10 could obviously increase the invasion capability of MCF-7, and downregulation of FAT10 could significantly decrease the invasion capability of MB-MDA-435 (P<0.01). FAT10 might increase the invasion capability of breast cancer cells by direct or indirect ways, and play an important role in invasion and metastasis of breast cancer. FAT10 might be an independent index for evaluation of breast cancer prognosis, and a potential target for breast cancer therapy, especially for triple-negative breast cancer.